Behavioural discovery for more precise CNS programs.
BioSymetrics combines high-throughput behavioural phenotyping, machine learning, and living-system validation to identify distinct neuropsychiatric states and guide mechanism-informed therapeutic discovery.
See the biological differences within behavioural disease.
Behavioural and psychiatric disorders can contain different biological states. A single endpoint can blur differences in disease biology and treatment response. We turn complex behaviour into structured evidence that helps partners decide where to look next.
Connect behavioural signals to therapeutic hypotheses.
We generate multidimensional behavioural signatures in vertebrate models, analyze automated imaging and phenomic data at scale, and identify reproducible response patterns. Our workflow connects phenotype to mechanism, target, and compound prioritization, then directs focused follow-up in living systems.
Build a sharper view of alcohol use disorder (AUD).
Our AUD program began with an NIH STTR-supported initiative that generated high-resolution signatures of ethanol exposure and withdrawal. Those signatures revealed distinct neurobehavioural patterns and opened a commercial discovery effort focused on differentiated candidates for biologically heterogeneous disease.
Our work turns behavioural signatures into a focused path for candidate discovery in AUD.
Measure multiple behavioural responses.
Our KCC2 program pairs chemical and genetic hyperexcitability models with computer vision to measure seizure rescue, sedation, and nociception in our screening workflow. Our work connects epilepsy research to broader conditions linked to inhibitory-tone dysregulation, including schizophrenia, autism spectrum disorders, and Rett syndrome.
Move behavioural evidence toward development decisions.
We connect behavioural readouts to target prioritization, compound triage, and mechanism assessment, then move selected hypotheses into human cell, organoid, or other validation systems. Partners can use our workflow to shape a new discovery program, advance an existing one, or develop assets for collaboration, licensing, and non-dilutive funding.
Interested in advancing a behavioural or neuropsychiatric CNS program?
Talk with us about applying our phenotyping and validation workflow to a disease model, target, compound, or existing dataset.
Partner with us